Madri­gal 'en­cour­aged' by ear­ly launch progress of land­mark NASH drug

Madri­gal Phar­ma­ceu­ti­cals is “mak­ing great progress” on the roll­out of its NASH drug Rezd­if­fra, ex­ec­u­tives said less than a month post-launch.

Rezd­if­fra was ap­proved in March as the first treat­ment for NASH, a de­bil­i­tat­ing liv­er dis­ease now al­so re­ferred to as meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis, or MASH. Madri­gal CEO Bill Si­bold told in­vestors on Tues­day that it’s too ear­ly to dis­close pre­scrip­tion da­ta, as the first ship­ments went out in April. But, he added, “What we’ve seen to date is re­al­ly en­cour­ag­ing.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER